JOP20200025A1 - مركبات جديدة تنشط مسار Nrf2 - Google Patents

مركبات جديدة تنشط مسار Nrf2

Info

Publication number
JOP20200025A1
JOP20200025A1 JOP/2020/0025A JOP20200025A JOP20200025A1 JO P20200025 A1 JOP20200025 A1 JO P20200025A1 JO P20200025 A JOP20200025 A JO P20200025A JO P20200025 A1 JOP20200025 A1 JO P20200025A1
Authority
JO
Jordan
Prior art keywords
novel compounds
nrf2 pathway
compounds activating
activating
compounds
Prior art date
Application number
JOP/2020/0025A
Other languages
English (en)
Inventor
Canela Nuria Trallero
Casals Laia Miret
Bas Marta Paradis
Tomillero Ivan Ramos
Benitez Miriam Gongora
Paniagua Carlos Heras
Cubero Omar Brun
Palomera Fernando Albericio
Duran Carlos Puig
Stefan Geschwindner
Andrew Davis
Stephen Fiacco
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of JOP20200025A1 publication Critical patent/JOP20200025A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات ببتيدية، حيث يكون للمركبات الببتيدية الصيغة (I)’، أو ملح مقبول صيدلانياً منه، أو ذوابة، أو أكسيد عند الموضع N، أو أيزومر فراغي منها: الصيغة (I)’ حيث R1؛ R2؛ s؛ t؛ u؛ Aa78 و G1 تكون كما تم تعريفها هنا. تكون المركبات الببتيدية مفيدة في تنشيط مسار Nrf2.
JOP/2020/0025A 2017-08-08 2018-08-08 مركبات جديدة تنشط مسار Nrf2 JOP20200025A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382558 2017-08-08
PCT/EP2018/071536 WO2019030298A1 (en) 2017-08-08 2018-08-08 NEW COMPOUNDS THAT ACTIVATE THE NRF2 PATH

Publications (1)

Publication Number Publication Date
JOP20200025A1 true JOP20200025A1 (ar) 2020-02-04

Family

ID=59677167

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0025A JOP20200025A1 (ar) 2017-08-08 2018-08-08 مركبات جديدة تنشط مسار Nrf2

Country Status (24)

Country Link
US (1) US20200255478A1 (ar)
EP (1) EP3665182A1 (ar)
JP (1) JP2020530022A (ar)
KR (1) KR20200035269A (ar)
CN (1) CN110997695A (ar)
AR (1) AR113100A1 (ar)
AU (1) AU2018314833B2 (ar)
BR (1) BR112019026306A2 (ar)
CA (1) CA3066698A1 (ar)
CL (1) CL2020000305A1 (ar)
CO (1) CO2020000617A2 (ar)
CR (1) CR20200056A (ar)
DO (1) DOP2020000017A (ar)
EA (1) EA202090432A1 (ar)
EC (1) ECSP20008530A (ar)
IL (1) IL272467A (ar)
JO (1) JOP20200025A1 (ar)
MA (1) MA49828A (ar)
MX (1) MX2020001481A (ar)
PE (1) PE20211460A1 (ar)
PH (1) PH12019502852A1 (ar)
SG (1) SG11201913161WA (ar)
TW (1) TW201919682A (ar)
WO (1) WO2019030298A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340226A (zh) * 2021-12-17 2023-10-16 德商３Ｂ製藥有限公司 碳酸酐酶ix配位體
WO2025248100A1 (en) * 2024-05-31 2025-12-04 Institut National de la Santé et de la Recherche Médicale Nrf2 activators for use in the treatment of vitiligo

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
DE69132850T2 (de) 1990-09-26 2002-05-29 Pharmachemie B.V., Haarlem Wirbelkammer-Pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
DK0674533T3 (da) 1992-12-18 1999-09-27 Schering Corp Inhalator for medikamenter i pulverform
TR199701169T1 (xx) 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Salmeterol i�in �l��lm�� doz inhaleri.
ATE209518T1 (de) 1995-06-21 2001-12-15 Asta Medica Ag Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
US7468418B2 (en) 2003-04-29 2008-12-23 Avi Biopharma., Inc. Compositions for enhancing transport of molecules into cells
ES2353018T3 (es) 2004-07-16 2011-02-24 Almirall, S.A. Inhalador para la administración de productos farmacéuticos en polvo, y un cartucho de polvo para uso con este inhalador.
RS53407B (sr) 2007-02-28 2014-10-31 Leo Pharma A/S Novi inhibitori fosfodiesteraze
WO2009147368A1 (en) 2008-06-04 2009-12-10 Medical Research Council Peptides
JP2012051826A (ja) * 2010-08-31 2012-03-15 Toray Ind Inc 環状ペプチド及びその修飾ペプチド並びにＫｅｌｃｈ様ＥＣＨ結合タンパク質１の結合阻害物質のスクリーニング方法
CA3092114A1 (en) 2011-05-05 2012-11-08 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CN103998458B (zh) 2011-08-30 2018-10-09 医学研究理事会 具有中央疏水域的细胞穿透肽
JP2015067579A (ja) * 2013-09-30 2015-04-13 国立大学法人東北大学 細胞透過性ペプチド及び当該ペプチドを含む医薬組成物。

Also Published As

Publication number Publication date
DOP2020000017A (es) 2020-02-28
MX2020001481A (es) 2020-03-20
MA49828A (fr) 2020-06-17
SG11201913161WA (en) 2020-01-30
EA202090432A1 (ru) 2020-06-08
AU2018314833A1 (en) 2020-01-02
CR20200056A (es) 2020-03-16
US20200255478A1 (en) 2020-08-13
PH12019502852A1 (en) 2020-09-28
IL272467A (en) 2020-03-31
KR20200035269A (ko) 2020-04-02
ECSP20008530A (es) 2020-05-29
TW201919682A (zh) 2019-06-01
BR112019026306A2 (pt) 2020-07-14
JP2020530022A (ja) 2020-10-15
AR113100A1 (es) 2020-01-29
CA3066698A1 (en) 2019-02-14
AU2018314833B2 (en) 2020-03-19
WO2019030298A1 (en) 2019-02-14
EP3665182A1 (en) 2020-06-17
PE20211460A1 (es) 2021-08-05
CO2020000617A2 (es) 2020-05-05
CL2020000305A1 (es) 2020-06-26
CN110997695A (zh) 2020-04-10

Similar Documents

Publication Publication Date Title
MX2020001352A (es) Compuestos, composiciones y metodos.
PH12020550703A1 (en) Sulfonamide compounds and use thereof
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX383935B (es) Amidas heterocíclicas como inhibidores de cinasa.
MY210123A (en) Tlr7/8 antagonists and uses thereof
SG10201811204RA (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
PH12018500071A1 (en) Plinabulin compositions
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MY193650A (en) Extracellular matrix compositions
WO2017011340A3 (en) Proteins and immunizing compositions containing klebsiella proteins and methods of use
MY181641A (en) Amino pyran ring derivative and composition and use thereof
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
MY188420A (en) Crystalline forms of (s)-afoxolaner
JOP20190163B1 (ar) منشط nrf2
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MY193239A (en) Novel b-lactamase inhibitors
PH12019502852A1 (en) Novel compounds activating the nrf2 pathway
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
IN2014MU00859A (ar)
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs